Blood Bank Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[238+ Pages Report] According to Facts & Factors, the global Blood Bank market size was estimated at USD 18.4 billion in 2025 and is expected to reach USD 32.6 billion by the end of 2034. The Blood Bank industry is anticipated to grow by a CAGR of 6.6% between 2026 and 2034. The Blood Bank Market is driven by the steady increase in blood transfusion demand from surgeries, trauma care, oncology, maternal health, and rising prevalence of blood disorders.

Market Overview

The blood bank market encompasses organizations and facilities responsible for the collection, testing, processing, storage, inventory management, and distribution of safe human blood and its components (packed red blood cells, fresh frozen plasma, platelets, cryoprecipitate) to hospitals, clinics, and other healthcare providers. These entities operate under strict regulatory oversight to ensure donor screening, infectious disease testing (HIV, HBV, HCV, syphilis, malaria, etc.), component separation, pathogen inactivation (where applicable), quality assurance, cold-chain logistics, traceability, and hemovigilance. The market includes public-sector national blood transfusion services, community and hospital-based blood banks, private standalone centers, mobile collection units, and plasma fractionation organizations, all working to maintain an adequate, safe, and equitable supply of blood products to meet clinical transfusion needs while minimizing wastage and adverse transfusion events.

Key Insights

• As per the analysis shared by our research analyst, the global Blood Bank market is estimated to grow annually at a CAGR of around 6.6% over the forecast period (2026-2034).
• In terms of revenue, the global Blood Bank market size was valued at around USD 18.4 billion in 2025 and is projected to reach USD 32.6 billion, by 2034.
• The global Blood Bank market is projected to grow at a significant rate due to rising surgical volumes, increasing prevalence of anemia, cancer, thalassemia, sickle-cell disease, and trauma cases requiring transfusions.
• Based on the Type, the Whole Blood Banks segment accounted for the largest market share of around 48% in 2025, due to it being the foundational model in most developing countries and many public-sector systems.
• Based on the Service, the Blood Collection segment accounted for the largest market share of around 38% in 2025, due to it being the entry point and highest-volume activity in every blood supply chain.
• Based on the End-User, the Hospitals segment accounted for the largest market share of around 65% in 2025, due to hospitals being the primary end-recipient of blood components for transfusion.
• Based on region, Asia Pacific was the leading revenue generator in 2025, with approximately 42% share, due to the world’s largest population, highest number of annual blood collections, and fastest-growing transfusion infrastructure in India and China.

Growth Drivers

• Rising Demand for Blood Transfusions in Clinical Care

Global increase in elective and emergency surgeries (cardiac, orthopedic, oncology, transplant), complicated deliveries, severe trauma, and hematologic disorders (thalassemia, sickle-cell disease, leukemia, aplastic anemia) continues to drive consistent year-on-year growth in red cell, platelet, plasma, and cryoprecipitate usage. Aging populations in both developed and emerging markets further amplify transfusion needs.

Successful large-scale voluntary blood donation campaigns, mobile collection drives, and community awareness programs — especially in Asia and Africa — are steadily increasing annual collections and reducing dependence on replacement/family donors, thereby expanding the overall addressable market for blood bank services and infrastructure.

Restraints

• Chronic Blood Shortages & Seasonal/Regional Imbalances

Many countries still face recurring shortages during peak demand periods (festivals, disasters, dengue outbreaks) due to insufficient voluntary donors, seasonal deferrals, and logistical challenges in reaching remote populations. This limits revenue stability for blood banks.

Very low reimbursement or no reimbursement for blood products in many public healthcare systems, combined with high operational costs (testing reagents, cold-chain, staff, quality assurance), creates financial strain and discourages private-sector participation or capacity expansion.

Opportunities

• Expansion of Component Therapy & Apheresis Centers

Increasing shift from whole-blood transfusion toward component therapy (packed RBCs, apheresis platelets, fresh frozen plasma, cryoprecipitate) creates demand for higher-value multi-bag systems, automated component separators, and specialized apheresis services — especially in urban tertiary hospitals and oncology/hematology centers.

Growing medical tourism in Asia (India, Thailand, Malaysia) and the Middle East for cardiac, orthopedic, and cancer treatments increases demand for high-quality, traceable blood components, supporting premium pricing and investment in advanced blood bank infrastructure.

Challenges

• High Cost of Infectious Disease Testing & Pathogen Reduction

Mandatory screening for HIV, HBV, HCV, syphilis, malaria, and emerging pathogens (Zika, West Nile, dengue, chikungunya) is expensive, especially NAT (nucleic acid testing), creating financial pressure on blood establishments in low-resource settings. Pathogen inactivation technologies remain limited to plasma and platelets in most countries due to cost and regulatory hurdles.

Maintaining cold-chain integrity during transport and storage in tropical climates and remote regions remains difficult, leading to product wastage and quality concerns that undermine confidence in the blood supply system.

Report Scope

Market Segmentation

The Blood Bank market is segmented by Type, Service, End-User, and region.

Based on Type Segment, the Blood Bank market is divided into Whole Blood Banks, Component Separation Banks, Apheresis Banks, and others. The most dominant segment is Whole Blood Banks, which holds the largest share due to it being the foundational model in most developing countries and many public-sector systems where whole blood is still widely transfused; it drives the market by generating the highest collection volumes and serving as the entry point for all downstream component preparation. The second most dominant is Component Separation Banks, growing faster in middle- and high-income settings; this segment contributes significantly to revenue growth by handling higher-value processing and distribution of packed RBCs, platelets, plasma, and cryoprecipitate.

Based on Service Segment, the Blood Bank market is divided into Blood Collection, Testing & Processing, Storage & Distribution, and others. The most dominant segment is Blood Collection, commanding the highest share because it is the highest-volume, most labor-intensive, and most visible activity in every blood supply chain; it propels market expansion by directly correlating with annual donation numbers and donor recruitment efforts. The second most dominant is Testing & Processing, which includes mandatory infectious disease screening and component separation; this segment advances the market through higher per-unit value and increasing regulatory complexity.

Based on End-User Segment, the Blood Bank market is divided into Hospitals, Blood Banks & Transfusion Centers, Research Institutes, and others. The most dominant segment is Hospitals, with the largest share owing to hospitals being the primary clinical end-user of blood components for transfusion; it fuels market growth by driving consistent demand through surgical, oncology, and emergency volumes. The second most dominant is Blood Banks & Transfusion Centers (standalone or hospital-affiliated), which act as intermediaries; this segment supports market development by managing collection, processing, and supply to multiple hospitals.

Recent Developments

• In early 2025, Indian Immunologicals Ltd. (Bharat Biotech group) commissioned a new state-of-the-art blood component separation center in Hyderabad to serve southern India.
• In late 2024, Terumo BCT expanded its automated blood component processing systems (Trima Accel apheresis + Reveos whole-blood automation) footprint in Southeast Asia and the Middle East.
• In mid-2024, Grifols opened a new plasma collection and fractionation facility in Indonesia, strengthening Southeast Asian supply of plasma-derived products.

Regional Analysis

• Asia Pacific to dominate the global market

Asia Pacific dominates the global Blood Bank market, driven by the world’s largest population, highest number of annual births, fastest-growing hospital bed capacity, and the largest absolute number of blood collections and transfusions. India and China together account for a very large share of global activity. India emerges as the single most dominant country, with the largest national blood transfusion service network, massive voluntary donation drives, thalassemia/sickle-cell burden, and rapid expansion of corporate hospital chains — all supported by government policies and NGO partnerships that continue to increase collection volumes and component therapy adoption.

North America holds a high-value position with near-universal component therapy, pre-storage leukoreduction, and advanced pathogen reduction. The United States dominates as the key country, with very high per-collection processing sophistication, strong traceability systems, and significant investment in apheresis and rare-donor programs.

Europe maintains a mature, high-quality position with centralized blood establishments and near-100% voluntary non-remunerated donation in most countries. Germany and France are the leading countries, with Germany benefiting from its domestic manufacturing strength and France from Établissement Français du Sang’s large-scale standardized operations.

Latin America is growing steadily, driven by blood safety improvements and increasing component separation. Brazil dominates as the primary country, with its public blood network (Hemobrás) and large population driving high collection volumes.

The Middle East & Africa region is heterogeneous but expanding in urban centers. Egypt and South Africa are the leading countries, with Egypt procuring large volumes through government tenders and South Africa operating a sophisticated national service with strong component therapy.

Competitive Analysis

The global Blood Bank market is dominated by players:

• Terumo Corporation
• Fresenius Kabi AG
• Grifols S.A.
• Haemonetics Corporation
• Macopharma
• JMS Singapore Pte Ltd.
• Neomedic Limited
• Nigale Sichuan Biomedical Co., Ltd.
• Suru International Pvt. Ltd.
• AdvaCare Pharma

The global Blood Bank market is segmented as follows:

By Type

• Whole Blood Banks
• Component Separation Banks
• Apheresis Banks
• Others

By Service

• Blood Collection
• Testing & Processing
• Storage & Distribution
• Others

By End-User

• Hospitals
• Blood Banks & Transfusion Centers
• Research Institutes
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America